Safety, efficacy and weight effect of two 11β‐ HSD1 inhibitors in metformin‐treated patients with type 2 diabetes
- 9 June 2014
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 16 (11) , 1070-1077
Abstract
Aims: We assessed safety and efficacy of two selective 11β‐HSD1 inhibitors (RO5093151/RO‐151 and RO5027383/RO‐838) in this randomized, controlled study in metformin‐treated patients with type 2 diabetes. Methods: Patients either received placebo (N = 21), RO‐151 BID 5 mg (N = 24) or 200 mg (N = 20) or RO‐838 QD 50 mg (N = 21) or 200 mg (N = 24) for 28 days. Metabolic assessments comprising of nine‐point plasma glucose profiles, oral glucose tolerance tests and determination of metabolic biomarkers including insulin, C‐peptide, glucagon, HbA1c and lipids were done at baseline and end of treatment. Results: Despite the short treatment duration, both RO‐151 and RO‐838 showed trends for improved HbA1c and consistent reductions in body weight (–0.86 to –1.67 kg) exceeding those observed with placebo (–0.28 kg, p = 0.019 for 200 mg RO‐151 vs. placebo). Insulin sensitivity parameters (e.g. HOMA‐IR and Matsuda‐Index) improved non‐significantly with 200 mg RO‐151. Lipid parameters did not consistently improve with either compound, but RO‐838 led to non‐significant increases in triglycerides and VLDL‐cholesterol versus placebo. Both compounds were well tolerated and showed inhibitory effects on 11β‐HSD1 activity based on urinary corticosteroid excretion. As reported for other 11β‐HSD1‐inhibitors increased concentrations of ACTH and adrenal androgen precursors were found with RO‐151, but not with RO‐838. Conclusions: Slight metabolic improvements were seen, in particular with RO‐151 high dose, however, the observed changes often did not reach statistical significance and were not clearly dose dependent. Studies of longer duration are needed to further investigate potential benefits and risks of these compounds.Keywords
Funding Information
- Roche
This publication has 21 references indexed in Scilit:
- 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defectsJournal of Clinical Investigation, 2013
- Management of diabetes across the course of disease: minimizing obesity-associated complicationsDiabetes, Metabolic Syndrome and Obesity, 2011
- Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertensionJournal of the American Society of Hypertension, 2011
- Increased Whole-Body and Sustained Liver Cortisol Regeneration by 11β-Hydroxysteroid Dehydrogenase Type 1 in Obese Men With Type 2 Diabetes Provides a Target for Enzyme InhibitionDiabetes, 2011
- Effects of an 11 β ‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndromeDiabetes, Obesity and Metabolism, 2011
- The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin MonotherapyDiabetes Care, 2010
- Therapeutic targets to reduce cardiovascular disease in type 2 diabetesNature Reviews Drug Discovery, 2009
- A Transgenic Model of Visceral Obesity and the Metabolic SyndromeScience, 2001
- Cortisol metabolism and the role of 11β-hydroxysteroid dehydrogenaseBest Practice & Research Clinical Endocrinology & Metabolism, 2001
- Cortisol Metabolism in Human Obesity: Impaired Cortisone->Cortisol Conversion in Subjects with Central AdiposityThe Journal of Clinical Endocrinology & Metabolism, 1999